A Study to Assess the Efficacy, Safety and Pharmacokinetics of EYU688 in Patients With Dengue Fever
ConditionDengue
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-60
SponsorNovartis Pharmaceuticals
About this trial
The purpose of this study is to characterize the effect on dengue viral load, fever clearance time as well as on clinical signs and symptoms with the treatment of EYU688 compared with placebo in patients with dengue fever.
Eligibility criteria
Qualifiers
Male or female, 18 - 60 years old (inclusive).
Nausea or vomiting.
Presence of rash, aches or pains including headache, muscle or joint pain.
Onset of fever ≤ 48 hours prior to treatment start.
Disqualifiers
Participants with any of abnormalities of clinical laboratory parameters.
Usage of any anticoagulant drugs.
Current significant medical conditions or illness that the investigator considers should exclude the participants, especially those that require continuation of other medications likely to have an interaction with the study drug.
Pregnant or nursing (lactating) women.
Trial design
Treatments tested in this trial
- EYU688
- Placebo
Treatment groups
108 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov